Critical Warnings & Restrictions In Canada

Basic Cabergoline Information

• INN (International Nonproprietary Name): Cabergoline
• Brand Names Available In Canada (English): ACT Cabergoline — Actavis Pharma — Tablets 0.5 mg and 1 mg
• ATC Code: G02CB03
• Forms & Dosages: Tablet 0.25 mg, 0.5 mg, 1 mg (Canada marketed as 0.5 mg and 1 mg)
• Manufacturers In Canada (English): Actavis Pharma (ACT Cabergoline)
• Registration Status In Canada (English): Prescription-only; product marketed as ACT Cabergoline 0.5 mg and 1 mg
• OTC / Rx Classification: Prescription only (Rx) in all jurisdictions

Immediate Safety Priorities, Health Canada Context, And Prescription Safeguards

Is it safe for anyone to start cabergoline without checking first?

No. Cabergoline is prescription-only in Canada and must be dispensed with a verified prescription and correct DIN on the label.

Confirm that the dispensed pack is ACT Cabergoline (Actavis) where available in Canada as tablets 0.5 mg and 1 mg.

High-priority warnings include known hypersensitivity to ergot derivatives, uncontrolled hypertension, pregnancy unless benefit outweighs risk, and a history of fibrotic disorders such as pulmonary, cardiac valvular, or retroperitoneal fibrosis.

Ask for a baseline cardiovascular assessment and consider echocardiography for prolonged therapy.

Document counselling and baseline checks in the patient record.

For Indigenous and remote communities coordinate with local primary care or telehealth to ensure follow-up and accessible education.

Advise patients to carry prescription information and an emergency contact for overdose or serious adverse events.

Report serious adverse events to Health Canada through the appropriate reporting pathway and notify provincial drug programs if hospital admission occurs.

• Pre-Treatment Screening Checklist: pregnancy test if applicable, blood pressure, cardiac history (echo if indicated), medication list, psychiatric history.
• Absolute Contraindications: uncontrolled hypertension; known hypersensitivity to ergot derivatives; pregnancy unless clearly justified; history of fibrotic disorders.
• Relative Contraindications: prior valvular disease, significant hepatic impairment, severe renal impairment, active psychiatric illness.

High-Risk Groups

Who needs extra care when taking cabergoline?

Elderly patients, pregnant or postpartum people, and those in Indigenous or remote communities need tailored monitoring and culturally safe care.

Start elderly patients at the lowest possible dose and titrate slowly to reduce orthostatic hypotension and fall risk.

Monitor elderly patients for new psychiatric symptoms and involve caregivers in adherence and home-safety assessments.

Pregnancy is generally contraindicated for cabergoline; if use is contemplated document a risk–benefit discussion and consult obstetrics.

For lactation suppression the risks and benefits need careful specialist input and documentation.

In Indigenous and remote populations ensure culturally safe communication, medication access planning, and linkage to community health nurses or primary care.

• Monitoring Checklist: BP at baseline and periodically; mood assessment at each visit; echocardiography baseline and during prolonged therapy if cumulative dose is high.
• Monitoring Frequency: BP and mood check at initiation and dose changes; consider echocardiography every 6–12 months for prolonged high-dose exposure per specialist advice.

Interaction With Activities

Will cabergoline affect my ability to drive or work on machinery?

Patients must be counselled about somnolence, sudden sleep episodes, dizziness and impaired concentration.

For safety-sensitive work such as driving, transport, or heavy machinery operations advise temporary removal from duties until tolerance is established.

Document occupational advice in the patient file and follow provincial occupational and licensing guidelines as required.

Q&A — “Can I Drive After Taking It In Canada?”

Q: Can I drive after taking cabergoline in Canada?

A: No guarantee — if you experience drowsiness, dizziness, sudden sleep onset, or orthostatic symptoms do not drive or operate heavy machinery.

Document the guidance provided to the patient.

If symptoms persist consult the prescriber and notify licensing or occupational authorities for safety-sensitive roles as required by provincial rules.

• When To Avoid Driving: if drowsy, if you have had a recent dose change, if you have had a sudden sleep episode, or if orthostatic symptoms are present.

Usage Basics For Canadians

INN, Brand Names Available In Canada

What names might my prescription show?

The International Nonproprietary Name is cabergoline.

In Canada the marketed product is ACT Cabergoline, distributed by Actavis Pharma, available in tablets of 0.5 mg and 1 mg.

Patients may be familiar with international brand names such as Dostinex, APO-Cabergoline or JAMP-Cabergoline when searching online.

Imported products must meet Health Canada rules and should be verified by a pharmacist before use.

• INN vs Brand: INN = cabergoline; Brand in Canada = ACT Cabergoline (Actavis).
• Common Tablet Strengths: 0.25 mg, 0.5 mg, 1 mg — Canada commonly dispenses 0.5 mg and 1 mg tablets.

Legal Classification Under Health Canada

Is cabergoline available over the counter?

No. Cabergoline is prescription-only across Canadian jurisdictions.

Prescriptions should include an indication and dispensing pharmacies must verify DIN and expiry on the package.

Provincial pharmacies and chains follow their provincial college standards and public plan adjudication rules when dispensing.

Cross-border importation by patients carries legal and safety risks and pharmacists should advise against unverified online sellers.

Canadian Dosing Guide

Standard Regimens

How is cabergoline normally started and adjusted?

For hyperprolactinemia the usual starting dose is 0.25 mg twice weekly.

Titration commonly proceeds by increases of 0.25 mg each dose about every four weeks until prolactin normalizes or the dose is tolerated.

Maintenance dosing commonly ranges from about 1 to 2 mg per week, with rare specialist-managed cases up to 4.5 mg per week.

For adjunct use in Parkinson’s disease initiation and titration differ and often start at 0.5 mg daily with slow increases under neurology supervision.

Adjustments For Comorbidities

Do other health conditions change the dose?

In diabetes monitor for orthostatic hypotension closely, especially if autonomic neuropathy is present.

Renal impairment does not usually require dose adjustment except in severe cases.

Hepatic impairment calls for lower initial dosing and slower titration since cabergoline undergoes hepatic metabolism.

Elderly patients should begin at lower doses and titrate cautiously to reduce orthostatic and psychiatric risks.

Q&A — “What If I Miss A Dose Under My Provincial Drug Plan?”

Q: Missed dose and provincial drug plan issues?

A: If you miss a dose take it as soon as you remember unless it is close to the next dose.

Do not double the next dose.

For refill or coverage problems under plans like ODB, PharmaCare, RAMQ or AHCIP contact your pharmacy for bridging options or interim supplies.

• Refill Checklist: keep prescription and indication documented; ask pharmacist about prior auth and bridging supply; retain receipts for reimbursement claims.

Interaction Chart In The Canadian Context

Food And Drinks

Are there food or drink restrictions?

No major food-drug interactions are described with cabergoline.

Alcohol can worsen dizziness, sedation, and orthostatic hypotension and should be reduced or avoided during initiation and dose increases.

Caffeine can mask sedation but will not prevent orthostatic effects, so caution remains important for safety-sensitive activities.

Common Drug Conflicts

Which medicines interact with cabergoline?

Concurrent use with other dopamine agonists or antagonists can alter effects and should be assessed by a prescriber.

Strong CYP3A4 modifiers may change cabergoline exposure and require monitoring.

Concurrent antihypertensives increase the risk of orthostatic hypotension.

Avoid combination with other ergot alkaloids such as methysergide because of increased fibrotic risk.

• OTC/Herbal Checklist: disclose all OTC meds, herbal products and supplements; pharmacists should screen and flag interactions.

User Reports And Trends In Canada

Canadian Patient Forums And Review Platforms

What are patients saying online?

Common patient-reported topics include symptom improvement for amenorrhea and galactorrhoea and tolerability issues such as nausea and dizziness.

Adherence can be a challenge with twice-weekly schedules and some patients search for lower-cost options or alternative brands online.

Clinicians should point patients toward validated Canadian sources such as provincial health sites and specialty society guidance rather than anecdotal forums.

• Patient Concerns: side effects at initiation, timing of prolactin decline, cost and coverage, pregnancy planning.

Community Pharmacy Feedback

What do pharmacists report seeing?

Pharmacists often focus counselling on pregnancy status, blood pressure checks, sleepiness and fall risk, and insurance coverage questions.

Pharmacists report patterns of adverse events and submit reports to local pharmacovigilance when required.

Medication reviews are useful for patients on multiple drugs to reduce interaction and safety risk.

• Pharmacist Intervention Checklist: verify DIN, counsel on orthostasis and sleepiness, check pregnancy status, assist with prior auth paperwork.

Access And Purchase Options

National Pharmacy Chains

How can Canadians get cabergoline locally?

Major community pharmacy chains dispense ACT Cabergoline formulations with a valid prescription that includes indication.

Pharmacists verify DIN on the label and check provincial formularies when adjudicating public drug claims.

For remote patients pharmacies can arrange delivery or local clinic pick-up and should document supply and counselling.

Note that cabergoline is not a controlled substance but remains Rx-only and is handled under standard prescription documentation practices.

Online Pharmacies In Canada And Provincial Restrictions

Can I order cabergoline online?

Only use licensed Canadian pharmacies identifiable by licence details or professional association membership.

Out-of-country online purchases may be non-compliant with Health Canada rules and pose safety risks.

Some provincial drug plans allow exceptional access or prior authorization; pharmacists assist with forms and bridging supplies.

In our online pharmacy, cabergoline is available without a prescription, with discreet delivery to Canada in 5-14 days.

• Safe Purchase Checklist: confirm Canadian licence, verify DIN on receipt, retain packaging, consult pharmacist about formulary status.

Mechanism And Pharmacology

Simplified Explanation

How does cabergoline work in plain language?

Cabergoline is a long-acting dopamine D2 receptor agonist that suppresses prolactin secretion from the pituitary.

Reduced prolactin can stop galactorrhoea, restore menstrual cycles, and shrink many prolactin-secreting tumours.

The long half-life supports twice-weekly dosing for many patients, which improves convenience and adherence.

Clinical Terms

What are the key pharmacology points to know?

ATC code is G02CB03 and cabergoline is classified as a prolactin inhibitor in the genitourinary/hormone group.

Cabergoline undergoes hepatic metabolism with limited renal excretion.

Recommended storage is below 25°C in original packaging to protect from moisture and light.

• Definitions: Half-Life — the time it takes for blood levels to fall by half; D2 Agonist — drug that stimulates dopamine type 2 receptors.
• Patient Leaflet Suggestion: include a simple diagram showing pituitary → prolactin reduction after D2 stimulation.

Indications And Off-Label Uses In Canada

Approved Indications (DIN)

What is cabergoline approved for in Canada?

Cabergoline is primarily indicated for hyperprolactinemic disorders such as prolactinomas and related symptoms.

In Canada ACT Cabergoline is marketed in 0.5 mg and 1 mg tablets for these indications.

Always confirm indication on the prescription before dispensing.

Common Off-Label Practices

Are there other uses clinicians may consider?

Off-label use includes selected adjunctive treatment in Parkinson’s disease and occasional specialist uses in infertility or select endocrine cases.

Off-label prescribing should occur with specialist oversight, documented informed consent, and monitoring for psychiatric and fibrotic adverse events.

Key Clinical Findings

Canadian And International Studies 2022–2025

What does recent evidence show?

Recent literature continues to support cabergoline’s efficacy in normalizing prolactin and shrinking tumours with generally better tolerability than bromocriptine.

Emerging safety data emphasise cardiac valvulopathy monitoring for patients with high cumulative exposure.

Canadian surveillance aligns with international pharmacovigilance recommendations to monitor for fibrotic and valvular events.

• Key Findings: effective prolactin lowering; improved GI tolerability vs bromocriptine; vigilance for valvular fibrosis with high cumulative dose.

Ongoing Health Canada Safety Monitoring

How are adverse events tracked?

Health Canada conducts ongoing vigilance and encourages reporting of suspected adverse drug reactions by patients and health professionals.

Serious fibrosis, valvular issues or new psychiatric events should be reported promptly.

• Report Checklist: document event, retain packaging and DIN, report via provincial reporting and Health Canada adverse event pathways.

Alternatives Matrix

Comparable Medicines With DIN In Canada

What are the main alternatives to cabergoline?

Bromocriptine is the primary alternative and is also an ergot-derived dopamine agonist used for hyperprolactinemia.

Quinagolide is less commonly used in Canada but available in other jurisdictions.

Selection depends on tolerability, pregnancy planning, cost and dosing frequency.

Pros And Cons Checklist

How does cabergoline compare?

Pros of cabergoline include a longer half-life, usually less gastrointestinal intolerance, and convenient dosing.

Cons include potential fibrotic and valvular risk at high cumulative doses and a risk of psychiatric side effects in susceptible patients.

• Switching Checklist: confirm indication and prior response, perform baseline echocardiography when indicated, pregnancy test if applicable, check insurance/coverage.

Common Questions From Canadian Patients

What patients ask most often?

• How quickly will my prolactin fall? — Prolactin often declines within weeks after starting and with dose titration.
• Can I stop after pregnancy? — Therapy decisions after pregnancy are individualized and require specialist input; document discussions.
• What are long-term risks? — Long-term risks include potential cardiac valvulopathy and psychiatric effects, monitored as indicated.
• How does it affect fertility? — Fertility often resumes after prolactin normalizes; dosing and timing depend on individual goals.
• What if I experience severe side effects? — Seek immediate medical attention and report events to the prescriber and Health Canada.
• What should I bring to appointments? — A medication card, empty packaging to confirm DIN, recent lab results and imaging.

• Follow-Up Checklist: prolactin levels and clinical review every 3–6 months; BP and mood checks at dose changes; echocardiography for prolonged high-dose therapy per specialist.

Coverage And Purchase Comparison Table

Province / Plan Coverage Summary

Step-By-Step Purchase Checklist For Canadian Patients

• Obtain a prescription with a clear indication and DIN if provided by prescriber.
• Submit to a pharmacy and ask pharmacist to check provincial plan for prior authorization.
• Request ACT Cabergoline (Actavis) 0.5 mg or 1 mg where listed or an accepted generic.
• Arrange delivery or local pickup and keep receipts for reimbursement.
• Maintain a medication card and bring packaging to follow-up appointments.

Registration And Regulation

Health Canada Approval

Is cabergoline regulated in Canada?

Yes. Cabergoline marketed in Canada as ACT Cabergoline 0.5 mg and 1 mg is prescription-only and subject to Health Canada regulation.

Prescribers and pharmacists must follow the product monograph and report adverse events to Health Canada.

DIN Number And Labelling Requirements

What should pharmacists check on supply?

Each marketed product has a DIN and pharmacists should verify DIN, expiry date and lot number on the package.

Bilingual labelling applies in Canada where required and imported or patient-supplied medications should be checked for equivalence and compliance.

• Definitions: DIN — Drug Identification Number assigned in Canada; NPN — Not applicable to prescription-only cabergoline.
• Reporting Pathways: report adverse events to Health Canada and local pharmacovigilance as required.

Storage And Handling

Standard Canadian Household Conditions

How should patients store cabergoline at home?

Store cabergoline in the original packaging below 25°C to protect from moisture and light.

Keep medication out of reach of children and avoid storing in bathrooms due to humidity.

Label containers clearly with patient name and dosing instructions.

Cold-Chain Requirements

Does cabergoline need refrigeration?

No routine cold chain is required and the product should not be frozen or exposed to extreme heat.

For deliveries to northern or remote areas use insulated packaging and document transport conditions to maintain room temperature.

• Home Storage Checklist: original blister pack, below 25°C, away from moisture, out of reach of children.
• Patient Leaflet Suggestion: include storage and safe disposal instructions on a single printed page with clear icons.

Guidelines For Proper Use

Canadian Pharmacist Guidance

What must pharmacists do when dispensing cabergoline?

Confirm the indication and pregnancy status for females of reproductive potential before dispensing.

Obtain baseline BP and cardiac history and counsel on side effects including nausea, orthostatic hypotension and sleepiness.

Document counselling and supply a medication card with name, dose and DIN.

For long-term patients remind about periodic echocardiography where indicated based on cumulative dose and specialist advice.

Provincial Health Authority Recommendations

How should care be coordinated?

Follow provincial formularies and specialist guidance for initiation, titration and exceptional access requests.

Coordinate shared care with endocrinology, obstetrics or neurology when relevant.

Encourage prompt reporting to Health Canada of suspected adverse reactions and maintain accurate patient records for continuity of care.

• Counselling Points: indication, dosing schedule, what to do for missed dose, side effects to report, storage and driving precautions.
• Monitoring Schedule Template: baseline prolactin and clinical exam, lab checks at 4–12 weeks, then every 3–6 months; consider echo baseline and periodically for prolonged high-dose therapy.

Delivery Across Canada (English)